Strosberg 2017 — NETTER-1 Trial

Citation: Strosberg J, El-Haddad G, Wolin E, et al; NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125-135. doi:10.1056/NEJMoa1607427.

Study design

• International, multicentre (41 centres, 8 countries), randomised, open-label, phase 3 trial (NETTER-1; NCT01578239). 229 patients randomised 1:1 (116 177Lu-Dotatate / 113 control), September 2012–mid-January 2016.
• Population: advanced, progressive, somatostatin-receptor-positive, well-differentiated (Ki-67 ≤20%) midgut NETs, with disease progression on octreotide LAR documented (over a maximum 3-year window) — i.e., a second-line population that had already failed first-line SSA therapy, unlike PROMID/CLARINET’s first-line populations.
• Experimental arm: 177Lu-Dotatate (peptide receptor radionuclide therapy, PRRT) 7.4 GBq IV every 8 weeks × 4 infusions (cumulative 29.6 GBq), plus supportive-care octreotide LAR 30 mg.
• Control arm: high-dose octreotide LAR 60 mg every 4 weeks.
• Primary endpoint: progression-free survival (PFS), independent central radiology review.
• A prespecified interim overall-survival analysis is reported; final OS analysis was planned for later (after 158 deaths or 5 years post-last-randomisation, whichever came first) and is not included in this paper.

Key findings

• Estimated PFS at month 20: 65.2% (177Lu-Dotatate) vs 10.8% (control); HR for progression or death 0.21 (95% CI 0.13–0.33) — a 79% lower risk of progression or death with 177Lu-Dotatate. Median PFS not reached (177Lu-Dotatate) vs 8.4 months (control).
• Objective response rate: 18% vs 3% (p<0.001).
• Interim overall survival analysis: 14 deaths (177Lu-Dotatate) vs 26 deaths (control); HR 0.40; p=0.004 — a 60% lower estimated risk of death, though the data were not yet mature enough to estimate median OS in either group, and this interim result did not cross the very conservative Lan-DeMets O’Brien-Fleming stopping boundary (p=0.000085) that would have been required to declare formal statistical significance at this interim look — treat as a promising but not yet confirmatory survival signal.
• Grade 3-4 adverse events (177Lu-Dotatate vs control): neutropenia 1% vs 0%, thrombocytopenia 2% vs 0%, lymphopenia 9% vs 0% — clinically significant myelosuppression occurred in <10% of patients.
• No evidence of renal toxicity during the observed follow-up (median 14 months), attributed in part to the concurrent amino-acid renal-protective infusion protocol used with each PRRT dose.
• One case of myelodysplastic syndrome was reported in the 177Lu-Dotatate group (0.9%) — flagged in the discussion as consistent with the known, roughly 2%, long-term MDS/leukaemia risk associated with PRRT reported in prior (non-randomised) literature; long-term surveillance is warranted.

Limitations

• Only an interim OS analysis is reported — the final, mature OS analysis was planned for a later date and is not captured in this source; the OS finding here should not be over-interpreted as definitive.
• Open-label design (PRRT vs octreotide dosing/administration is not practically blindable).
• Midgut-only population, second-line (post-SSA-progression) setting — does not address PRRT’s role as first-line therapy, in non-midgut primaries, or in higher-grade (Ki-67 >20%) disease.
• Myelosuppression, while uncommon at clinically significant grades, and the rare but serious MDS risk both require ongoing long-term surveillance not fully characterized within this trial’s follow-up window.

Relevance

Closes the primary-literature gap flagged in Small Bowel Neuroendocrine Tumors (NETs)‘s Open items for 177Lu-Dotatate/PRRT/NETTER-1 — that page previously narratively summarized this trial via a textbook chapter, paraphrasing the hazard ratio as “79% progression-free survival improvement.” That framing is confirmed directionally accurate here (HR 0.21 = 79% lower risk of progression or death) but is more precisely a risk reduction, not a percentage increase in PFS duration — worth using the more precise framing (median PFS not reached vs 8.4 months) going forward. NETTER-1 establishes PRRT as an effective second-line option after SSA progression, complementing Rinke 2009 - PROMID Trial and Caplin 2014 - CLARINET Trial (first-line SSA evidence) and Yao 2016 - RADIANT-4 Trial (alternative second-line targeted-therapy option, everolimus) as the wiki’s four primary-literature NET trials.